Abstract
The cell cycle is governed by cyclin dependent kinases (cdks), which are activated by binding of cyclins, inhibited by cdk inhibitors and regulated by phosphorylation and dephosphorylation. Exposure to high dose dihydrotestosterone (DHT) inhibits population growth of the human prostate carcinoma cell line, LNCaP. To determine the mechanism of growth arrest by high dose DHT, we assayed the changes in cell cycle profile and the cell cycle regulators that mediate these effects. Treatment of asynchronously growing LNCaP cells with 100 nM DHT caused a G1 arrest. The proportion of cells in S phase fell from 22 to 2%, while the G1 fraction rose from 74 to 92% by 24 h. Loss of phosphorylation of the retinoblastoma protein was noted and cdk4 and cyclin E/cdk2 activities fell. Inhibition of these G1 cyclin dependent kinases was not due to loss of either cyclin or cdk proteins nor to increases in the cdk inhibitors p16INK4A and p21Cip1. p21Cip1 protein levels remained constant, and cyclin E-associated p21Cip1 fell, suggesting that p21Cip1 is not relevant to this form of cyclin E/cdk2 inhibition. Of note, total p27Kip1 levels and cyclin E-associated p27Kip1 increased as cells arrested and the amount of the CAK activated cdk2 bound to cyclin E decreased. p27Kip1 immunodepletion experiments demonstrated that the DHT-mediated increase in p27Kip1 was sufficient to fully saturate and inhibit target cyclin E/cdk2. The inhibition of cyclin E/cdk2 by p27Kip1 contributes to G1 arrest of LNCaP following high dose DHT. p27Kip1 may be a key effector of androgen dependent growth modulation in prostate cancer cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bates S and Peters G. . 1995 Sem. Cancer Biol. 6: 73–82.
Berns EM, de Boer W and Mulder E. . 1986 Prostate 9: 247–259.
Cariou S, Catzavelos C and Slingerland JM. . 1998 Breast Cancer Res. Treat. 52: 29–41.
Casaccia-Bonnefil P, Tikoo R, Kiyokawa H, Friedrich Jr V, Chao MV and Koff A. . 1997 Genes Dev. 11: 2335–2346.
Catalona WJ. . 1994 N. Engl. J. Med. 331: 996–1004.
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM. . 1997 Nature Med. 3: 227–230.
Chellappan S, Hiebert SW, Mudryl M, Horowitz J and Nevins JR. . 1991 Cell 65: 1053–1061.
Chen Y, Robles AI, Martinez LA, Liu F, Gimenez-Conti IB and Conti CJ. . 1996 Cell Growth Differ. 7: 1571–1578.
Coats S, Flanagan M, Nourse J and Roberts JM. . 1996 Science 272: 877–880.
Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J and Scher HI. . 1998 J. Natl. Cancer Inst. 90: 1284–1291.
Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D and Lieskovosky G. . 1998 J. Natl. Cancer Inst. 90: 916–920.
DeGregori J, Kowalik T and Nevins JR. . 1995 Mol. Cell Biol. 15: 4215–4224.
Dulic V, Lees E and Reed SI. . 1992 Science 257: 1958–1961.
Enders GH, Koh J, Rustigi AK, Missero C and Harlow E. . 1995 Oncogene 12: 1239–1245.
Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A. . 1997 Cancer Res. 57: 3381–3385.
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Polyak K, Firpo E, Tsai L, Broudy V, Perlmutter RM, Kaushansky K and Roberts JM. . 1996 Cell 85: 733–744.
Gu Y, Rosenblatt J and Morgan DO. . 1992 EMBO J. 11: 3995–4005.
Guo Y, Sklar GN, Borkowski A and Kyprianou N. . 1997 Clin. Cancer Res. 3: 2269–2274.
Hakimi JM, Rondinelli RH, Schoenberg MP and Barrack ER. . 1996 World J. Urol. 14: 329–337.
Hartwell L. . 1992 Cell 71: 543–546.
Hengst L and Reed SI. . 1996 Science 271: 1861–1864.
Hengst L, Dulic V, Slingerland J, Lees E and Reed SI. . 1994 PNAS USA 91: 5291–5294.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP. . 1983 Cancer Res. 43: 1809–1818.
Huggins C, Stevens RE and Hodges CV. . 1941 Arch. Surg. 43: 209–220.
Hunter T and Pines J. . 1994 Cell 79: 573–582.
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW. . 1979 Invest. Urol. 17: 16–23.
Kato JY, Matsuoka M, Polyak K, Massague J and Sherr CJ. . 1994 Cell 79: 487–496.
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilczynski S, Young YL, Bartram CR and Koeffler HP. . 1995 Cancer Res. 55: 2266–2269.
Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA and Lee C. . 1996 Endocrinology 137: 991–999.
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A. . 1996 Cell 85: 721–732.
Koff A, Ohtsuki M, Polyak K, Roberts JM and Massague J. . 1993 Science 260: 536–539.
Kokontis JM, Hay N and Liao S. . 1998 Mol. Endocrinol. 12: 941–953.
Laiho M, Weis FMB and Massague J. . 1990 J. Biol. Chem. 265: 18518–18524.
Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS and Kozlowski JM. . 1995 Endocrinology 136: 796–803.
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M. . 1997 Nature Med. 3: 231–234.
Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CA and Kato J-Y. . 1994 Mol. Cell. Biol. 14: 2066–2076.
Menjo M, Kaneko Y, Ogata E, Ikeda K and Nakanishi M. . 1998 Oncogene 17: 2619–2627.
Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H and Koff A. . 1997 J. Biol. Chem. 272: 7093–7098.
Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A and Pagano M. . 1999 Genes Dev. 13: 1181–1189.
Morgan DO. . 1995 Nature 374: 131–134.
Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K and Akiyoshi T. . 1997 Nat. Med. 3: 593.
Murray AW. . 1992 Nature 359: 599–604.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY and Nakayama K-E. . 1996 Cell 85: 707–720.
Pagano M, Beer-Romero P, Glass S, Tam S, Theodoras A, Rolfe M and Draetta G. . 1996 Seventh Pezcoller Symposium, Cancer Genes: Functional Aspects 7: 241–254.
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M. . 1995 Science 269: 682–685.
Parry D, Bates S, Mann DJ and Peters G. . 1995 EMBO J. 14: 503–511.
Peehl DM. . 1994 In: Atlas of Human Tumour Cell Lines. Hay R, Park JG and Gazdar AF. (eds).. Academic Press, Inc.: San Diego.
Peeling WB. . 1989 Urology 33: 45–52.
Peng D, Fan Z, Lu Y, DeBlasio T, Scher H and Mendelsohn J. . 1996 Cancer Res. 56: 3666–3669.
Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD and Vogelstein B. . 1995 Cancer Res. 55: 1206–1210.
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A. . 1994a Genes Dev. 8: 9–22.
Polyak C, Lee M-H, Erdjument-romage H, Koff A, Roberts J, Tempst P and Massague J. . 1994b Cell 78: 59–66.
Ponce-Castaneda MV, Lee M-H, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J and Cordon-Cardo C. . 1995 Cancer Res. 55: 1211–1214.
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM. . 1997 Nature Med. 3: 222–225.
Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D and Slingerland J. . 1994 J. Cell Sci. 18: 69–73.
Reynisdottir I, Polyak K, Iavarone A and Massague J. . 1995 Genes Dev. 9: 1831–1845.
Rivard N, L'Allemain G, Bartek J and Pouyssegur J. . 1996 J. Biol. Chem. 271: 18337–18341.
Sandhu C, Garbe J, Daksis J, Pan C-H, Bhattacharya N, Yaswen P, Koh J, Slingerland J and Stampfer MR. . 1997 Mol. Cell Biol. 17: 2458–2467.
Schneider BL, Yang QH and Futcher AB. . 1996 Science 272: 560–562.
Sheaff RJ, Groudine M, Gordon M, Roberts JM and Clurman BE. . 1997 Genes Dev. 11: 1464–1478.
Sherr CJ. . 1994 Cell 79: 551–555.
Sherr CJ and Roberts JM. . 1995 Genes Dev. 9: 1149–1163.
Sherr CJ and Roberts JM. . 1999 Genes Dev. 13: 1501–1512.
Slingerland JM, Hengst L, Pan C-H, Alexander D, Stampfer MR and Reed SI. . 1994 Mol. Cell Biol. 14: 3683–3694.
Solomon MJ. . 1993 Curr. Opin. Cell Biol. 5: 180–186.
St.Croix B, Florenes V, Rak A, Flanagan JW, Bhattacharya N, Slingerland JM and Kerbel RS. . 1996 Nature Med. 2: 1204–1210.
Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF. . 1978 Int. J. Cancer 21: 274–281.
Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M and Loda M. . 1997 Cancer Res. 57: 1259–1263.
Toyoshima H and Hunter T. . 1994 Cell 78: 67–74.
Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH and Slingerland JM. . 1998 Cancer Res. 58: 542–548.
Tsvetkov LM, Yeh KH, Lee SJ, Sun H and Zhang H. . 1999 Curr. Biol. 9: 661–664.
Tyers M. . 1996 Proc. Natl. Acad. Sci. USA 93: 7772–7776.
Vlach J, Hennecke S and Amati B. . 1997 EMBO J. 16: 5334–5344.
Wang QM, Jones JB and Studzinski GP. . 1996 Cancer Res. 56: 264–267.
Yang RM, Naitoh J, Murphy M, Wang H-J, Philipson J, deKernion JB, Loda M and Reiter RE. . 1998 J. Urol. 159: 941–945.
Zi X, Grasso AW, Kung HJ and Agarwal R. . 1998 Cancer Res. 58: 1920–1929.
Acknowledgements
We thank Jeff Donovan for helpful discussions and advice in the design of the antisense p27 experiments. This work was funded by a grant from the US Army Department of Defense Prostate Cancer Research Program to JM Slingerland. J Tsihlias was supported by a Terry Fox Fellowship from the National Cancer Institute of Canada. JM Slingerland is supported by Cancer Care Ontario.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsihlias, J., Zhang, W., Bhattacharya, N. et al. Involvement of p27Kip1 in G1 arrest by high dose 5α-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19, 670–679 (2000). https://doi.org/10.1038/sj.onc.1203369
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203369
Keywords
This article is cited by
-
High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling
Cell Death Discovery (2022)
-
Discovery proteomics defines androgen-regulated glycoprotein networks in prostate cancer cells, as well as putative biomarkers of prostatic diseases
Scientific Reports (2021)
-
Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death
Cell Death & Disease (2021)
-
The polyglutamine-expanded androgen receptor responsible for spinal and bulbar muscular atrophy inhibits the APC/CCdh1 ubiquitin ligase complex
Scientific Reports (2016)
-
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers
The EMBO Journal (2012)